Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||A phase II trial of cisplatin and interferon alpha 2b in patients with advanced bladder cancer.|
|Citation:||American Journal of Clinical Oncology CCT, 1997; 20(3):319-321|
|Abstract:||Twenty-two patients with advanced transitional cell bladder cancer were treated in a phase II trial exploring the possible synergy of cisplatin and interferon alpha 2b. Of the 20 evaluable patients, 7 (35%) had a partial response to the treatment, and only 6 patients were able to complete the full planned six cycles of treatment. Response rates, duration of responses, and overall survival of our patients are not superior to those expected by cisplatin alone.|
|Keywords:||Humans; Carcinoma, Transitional Cell; Disease Progression; Cisplatin; Interferon-alpha; Recombinant Proteins; Antineoplastic Combined Chemotherapy Protocols; Neoplasm Staging; Disease-Free Survival; Treatment Outcome; Drug Synergism; Female; Male; Urinary Bladder Neoplasms; Interferon alpha-2|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.